Mersana Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Mersana Therapeutics, Inc. carries a market capitalization of 145.36M, placing it among publicly traded companies globally. Its enterprise value stands at -15.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 145.36M |
| Enterprise Value | -15.49M |
Share Statistics
Mersana Therapeutics, Inc. currently has 4.99M shares outstanding.
| Shares Outstanding | 4.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.16, and the price-to-book ratio stands at -0.04.
| PE Ratio | N/A |
| PS Ratio | 1.16 |
| PB Ratio | -0.04 |
| P/TBV Ratio | -0.65 |
| P/FCF Ratio | -0.52 |
| P/OCF Ratio | -0.52 |
Enterprise Valuation
| EV / Sales | 1.74 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Mersana Therapeutics, Inc. maintains a current ratio of 1.39, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -3.85, indicating conservative leverage, while an interest coverage ratio of -24.14 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.39 |
| Quick Ratio | 1.31 |
| Debt / Equity | -3.85 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -24.14 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -60.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Mersana Therapeutics, Inc.'s stock has gained approximately 62.00557% over the past 52 weeks. The 50-day moving average sits at 22.88, while the 200-day moving average is 11.99.
| Beta (5Y) | N/A |
| 52-Week Price Change | 62.00557% |
| 50-Day Moving Average | 22.88 |
| 200-Day Moving Average | 11.99 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mersana Therapeutics, Inc. generated 33.18M in revenue and converted that into -70.08M in net income, yielding earnings per share of -14.09. EBITDA reached -66.29M, while operating income came in at -67.38M.
| Revenue | 33.18M |
| Gross Profit | N/A |
| Operating Income | -67.38M |
| Pretax Income | -70.08M |
| Net Income | -70.08M |
| EBITDA | -66.29M |
| EBIT | -67.38M |
| Earnings Per Share (EPS) | -14.09 |
Balance Sheet
Mersana Therapeutics, Inc. holds 56.39M in cash and equivalents against 2.29M in total debt, resulting in a net debt position of -56.39M. Total book value stands at -951.52M, with working capital of 16.72M providing operational flexibility.
| Cash & Cash Equivalents | 56.39M |
| Total Debt | 2.29M |
| Net Debt | -56.39M |
| Equity (Book Value) | -951.52M |
| Book Value Per Share | -191.26 |
| Working Capital | 16.72M |
Cash Flow
Mersana Therapeutics, Inc. produced -74.37M in operating cash flow over the past twelve months.
| Operating Cash Flow | -74.37M |
| Capital Expenditures | N/A |
| Free Cash Flow | -74.37M |
| FCF Per Share | -14.95 |
Margins
Mersana Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -203.06 and net profit margin of -211.21 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -203.06 |
| Pretax Margin | -211.21 |
| Profit Margin | -211.21 |
| EBITDA Margin | -199.79 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 67.02 |
| FCF Yield | -192.64 |
Stock Splits
Mersana Therapeutics, Inc.'s most recent stock split took place on July 28, 2025 with a 25:1 split ratio.
| Last Split Date | 7/28/2025 |
| Split Ratio | 25:1 |
Scores
Mersana Therapeutics, Inc. posts an Altman Z-Score of -23.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -23.76 |